Qualcomm’s subsidiary Qualcomm Life will partner with Boehringer Ingelheim to develop a connectivity solution for Boehringer’s platform inhaler, the RESPIMAT inhaler with a view to improve chronic obstructive pulmonary disease (COPD) treatment results.
RESPIMAT is an inhalation spray which is administered through two puffs once each day to control symptoms induced by COPD in adults.
Based on the 2net Design platform, Qualcomm Life will develop the prototype of a small, wireless, low-power, disposable module for the RESPIMAT inhaler.
2net Design is a platform to design the communications components of connected medical devices as well as disposable drug delivery devices and disposable diagnostic devices for condition specific connected therapies.
The fully integrated inhaler can seamlessly connect with Qualcomm Life’s 2net Platform which will enable the tracking of puffs from the RESPIMAT inhaler.
The information can then be relayed to health care providers and the patients who have been prescribed with the RESPIMAT medicines.
Qualcomm Life president Rick Valencia said: “Qualcomm Life is committed to powering the Internet of Medical Things to ultimately enable intelligent care to be delivered wherever the patient may be.
“We are excited to be collaborating with an industry leader like Boehringer Ingelheim to deliver a more seamless digital health experience that can enable their COPD patients to better manage their disease.”
The collaboration is expected to combine Boehringer experience in COPD medicines with Qualcomm Life’s expertise in developing reference designs for wireless, single-use and small integrated modules to support administration of daily treatment regimens.